Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
COCH Stock Forecast 2026-2027
$0.70
Current Price
$53.69M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to COCH Price Targets
+258.0%
To High Target of $2.50
+258.0%
To Median Target of $2.50
+258.0%
To Low Target of $2.50
COCH Price Momentum
+4.5%
1 Week Change
-10.3%
1 Month Change
-46.6%
1 Year Change
+6.1%
Year-to-Date Change
-63.4%
From 52W High of $1.91
+92.4%
From 52W Low of $0.36
📊 TOP ANALYST CALLS
Did COCH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Envoy Medical is one of their latest high-conviction picks.
Latest COCH Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, COCH has a bullish consensus with a median price target of $2.50 (ranging from $2.50 to $2.50). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.70, the median forecast implies a 258.0% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 258.0% upside. Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 258.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COCH Analyst Ratings
1
Buy
0
Hold
0
Sell
COCH Price Target Range
Low
$2.50
Average
$2.50
High
$2.50
Current: $0.70
Latest COCH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COCH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $2.50 |
| May 27, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $9.50 |
| Apr 21, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $9.25 |
| Dec 6, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $9.00 |
| Oct 14, 2024 | Brookline Capital | Tyler Bussian | Buy | Initiates | $9.00 |
| Sep 3, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $8.75 |
| Jun 24, 2024 | Ascendiant Capital | Edward Woo | Buy | Initiates | $8.50 |
| Apr 3, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $6.00 |
| Dec 21, 2023 | Northland Capital Markets | Carl Byrnes | Outperform | Initiates | $N/A |
| Nov 28, 2023 | Lake Street | Frank Takkinen | Buy | Initiates | $3.00 |
Envoy Medical, Inc. (COCH) Competitors
The following stocks are similar to Envoy Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
COCH
Envoy Medical
mkt cap
54.48M
Envoy Medical, Inc. (COCH) Financial Data
Valuation Metrics
Market Cap
$53.69M
Enterprise Value
$51.66M
P/E Ratio
N/A
PEG Ratio
-2.4x
Price/Sales
226.0x
Growth & Margins
Revenue Growth (YoY)
+78.6%
Gross Margin
-181.3%
Operating Margin
-8,260.0%
Net Margin
-262.7%
EPS Growth
+78.6%
Financial Health
Cash/Price Ratio
+7.0%
Current Ratio
0.5x
Debt/Equity
-0.1x
ROE
+243.6%
ROA
-137.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Envoy Medical, Inc. (COCH) Business Model
About Envoy Medical, Inc.
What They Do
Develops innovative medical devices for hearing healthcare.
Business Model
Envoy Medical generates revenue by designing and developing advanced medical devices specifically for individuals with hearing loss. Their flagship products, which integrate cutting-edge technology, are sold to healthcare providers and directly to consumers, enhancing auditory performance and improving patient outcomes.
Additional Information
The company operates within the medical device industry, impacting audiology and otolaryngology sectors. Envoy Medical is committed to ongoing research and development, positioning itself as a leader in hearing health technologies and addressing the needs of an increasing demographic requiring sophisticated hearing solutions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
43
CEO
Mr. Brent T. Lucas Esq.
Country
United States
IPO Year
2023
Website
www.envoymedical.comEnvoy Medical, Inc. (COCH) Latest News & Analysis
Latest News
Quick Summary
Envoy Medical, Inc. (NASDAQ: COCH) appointed Chas McKhann to its Board of Directors. McKhann is a seasoned med tech executive with a proven track record in driving commercialization and shareholder value.
Why It Matters
Chas McKhann's appointment to Envoy Medical's Board signals potential for enhanced commercialization and growth, likely boosting investor confidence and increasing shareholder value.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Envoy Medical (NASDAQ: COCH) reports first three patients in its pivotal trial for the Acclaim® cochlear implant have completed 12-month evaluations, advancing towards FDA PMA submission.
Why It Matters
Successful completion of 12-month evaluations by trial patients signals progress towards FDA approval, potentially boosting Envoy Medical's market position and stock value.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Envoy Medical received FDA approval to advance its Acclaim® Cochlear Implant trial, extinguished $32M in debt, and raised up to $78M in a capital offering. The pivotal trial enrollment is complete.
Why It Matters
FDA approval and trial expansion signal potential market entry for Envoy Medical's innovative cochlear implant, while debt reduction and capital raise enhance financial stability, boosting investor confidence.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Envoy Medical Inc. (NASDAQ: COCH) has completed enrollment for its pivotal clinical trial of the Acclaim® cochlear implant, aiming for FDA approval, marking a significant milestone in the sector.
Why It Matters
Completion of enrollment in a pivotal clinical trial positions Envoy Medical for potential FDA approval, which could lead to significant market opportunities and revenue growth, impacting stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Envoy Medical Inc. (NASDAQ: COCH) has regained compliance with Nasdaq Listing Rule 5550(b)(2) after previously being notified of non-compliance due to a market value shortfall.
Why It Matters
Envoy Medical's compliance with Nasdaq's listing requirements restores investor confidence, potentially stabilizing its stock price and attracting institutional interest.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Envoy Medical (NASDAQ: COCH) announced three new patents, enhancing its intellectual property and competitive edge in the cochlear implant market, emphasizing its focus on fully implanted devices.
Why It Matters
Envoy Medical's new patents enhance its competitive edge in the cochlear implant market, potentially leading to increased market share and revenue growth, attracting investor interest.
Source: Newsfile Corp
Market Sentiment:
Neutral
Frequently Asked Questions About COCH Stock
What is Envoy Medical, Inc.'s (COCH) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Envoy Medical, Inc. (COCH) has a median price target of $2.50. The highest price target is $2.50 and the lowest is $2.50.
Is COCH stock a good investment in 2026?
According to current analyst ratings, COCH has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COCH stock?
Wall Street analysts predict COCH stock could reach $2.50 in the next 12 months. This represents a 258.0% increase from the current price of $0.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Envoy Medical, Inc.'s business model?
Envoy Medical generates revenue by designing and developing advanced medical devices specifically for individuals with hearing loss. Their flagship products, which integrate cutting-edge technology, are sold to healthcare providers and directly to consumers, enhancing auditory performance and improving patient outcomes.
What is the highest forecasted price for COCH Envoy Medical, Inc.?
The highest price target for COCH is $2.50 from Yi Chen at HC Wainwright & Co., which represents a 258.0% increase from the current price of $0.70.
What is the lowest forecasted price for COCH Envoy Medical, Inc.?
The lowest price target for COCH is $2.50 from Yi Chen at HC Wainwright & Co., which represents a 258.0% increase from the current price of $0.70.
What is the overall COCH consensus from analysts for Envoy Medical, Inc.?
The overall analyst consensus for COCH is bullish. Out of 5 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $2.50.
How accurate are COCH stock price projections?
Stock price projections, including those for Envoy Medical, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 2:28 AM UTC